The influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not. Here using in vivo and in vitro models we demonstrate the impact epithelial cells and the mammary microenvironment can exert on breast cancer cells. Under specific conditions, signals that originate in epithelial cells can induce phenotypic and genotypic changes in cancer cells. We have termed this phenomenon "cancer cell redirection." Once breast cancer cells are redirected, either in vivo or in vitro, they lose their tumor forming capacity and undergo a genetic expression profile shift away from one that supports a cancer profile towards one that supports a non-tumorigenic epithelial profile. These findings indicate that epithelial cells and the normal microenvironment influence breast cancer cells and that under certain circumstances restrict proliferation of tumorigenic cells.
Based on our results we conclude that AREG is involved in regulating the proliferation and migration of erbB2/HER2-positive breast cancer cells.
Breast cancer is the most common form of cancer among women, affecting one eigth of the female population. While advances in clinical management and therapeutic modalities have been achieved, serious limitations in the improvement of outcomes after the diagnosis remain, largely due to the complexity of the underlying biology. Studying the mechanism that makes cancer cells tumorigenic and how they can lose the ability to cause malignant formations is the first step towards understanding complex mechanisms of this disease. The normal mammary microenvironment can redirect cells to assume a normal mammary epithelial phenotype. This phenomenon also applies to tumorigenic cells; cancer cells lose their tumor-forming capacity and differentiate, assuming a normal, non-tumorigenic phenotype. This phenomenon has been termed “cancer cell redirection.” Comparing cells that went through this transformation with original cancer cells, features that identify tumorigenic activity can be acknowledged. We have established an in vitro model of cancer cell redirection, in which HER2+ breast cancer cells are grown alone or in co-culture with normal human breast epithelial cells. The ratios of cells used in co-cultures, 1:1 and 1:50 (cancer: normal) were previously established through in vivo and in vitro studies. Redirection was confirmed by immunostaining. The metric used to determine cancer cell redirection was the absence of receptor tyrosine kinase phosphorylation without a change in surface expression of the receptor. HER2 and P-HER2 expression were both present in the HER2+ cancer cells and in the: MCF10A and 1:1 co-cultures. However, HER2 expression was observed in 1:50 co-cultures, but an absence of P-HER2 was noted. Based on attenuation of receptor phosphorylation in the 1:50 co-cultures we can confirm the breast cancer cell redirection, which matches our previous results. Furthermore, alteration of HER2 dimerization patterns in redirected cells were investigated. The capacity of cancer and redirected cells to form tumors was examined with use of mammosphere assay. Formation of mammospheres has correlated to stem cell function and tumor-initiation capacity. The HER2+ breast cancer cell lines formed significantly higher numbers of spheres compared to the non-tumorigenic breast epithelial cells. Mammosphere formation is decreased in redirected cancer cells. Breast cancer stem cells are HER2+ regardless of pathological or genetic classification. This suggests that HER2 expression is not only a target in HER2+ breast cancer but should be targeted in all breast cancers to prevent breast cancer stem cells from recapitulating tumors following treatment. Our data demonstrates that by attenuating activity of HER2 theses cancer cells lose the capacity to form tumors in vivo and lose their cancer phenotype in vitro. Citation Format: Anastasia Frank-Kamenetskii, Julia M. Mook, Brian W. Booth. Redirection of human HER2-positive breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3092.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.